
Clamor has risen around India & South Africa’s proposal seeking Intellectual Property Rights or IPR waivers for easier access to COVID-19 medicines. But what choices do nations have if the negotiations fail to bear fruit? And, if the debates actually lead to something concrete, is the pharmaceutical industry ready to...










